(2012 / A -08). A total of 38 Wistar albino rats weighing between 150 and 200 g were used. During the study, the animals were kept in automatically regulated chambers under light and dark conditions, each lasting for 12 h a day, at an ambient temperature of 22 ± 2 °C and 45%-50% humidity. All rats were fed standard pellets, and every day they were given fresh tap water. After anesthetizing the animals with 50 mg/kg intramuscular (i.m.) ketamine and 5 mg/kg i.m. xylazine, they were brought into special silent cabins for the application of subsequent procedures.
Otoacoustic emission measurements were used to evaluate the hearing functions of all animals. In otoacoustic emission measurements, distortion-product otoacoustic emission test (DPOAE) values were used.
Rats were randomly divided into 4 groups. The control group consisted of 7 rats, which received physiologic saline at daily doses of 5 mL intraperitoneally (i.p.) between days 0 and 5. The cisplatin group comprised 12 rats that received cisplatin i.p. at daily doses of 8 mg/kg between days zero and 2. The cisplatin + lycopene group included 12 rats that received cisplatin (8 mg/kg i.p. daily between days 0 and 2) plus lycopene (5 mg/kg i.p. daily between days 0 and 5). The lycopene group contained 7 rats, which received lycopene (5 mg/kg i.p. daily). In all groups, DPOAE measurements were performed on days 0, 1, 2, and 5.
Otoacoustic emission measurements
The study included rats with normal DPOAE values. For DPOAE test measurements, the GSI Audera DPOAE (Grason Stadler, Madison, WI, USA) device was used. The otoacoustic emission probe was placed into the external auditory canal. For accuracy, the implantation and calibration of the probe were examined using automated measurement systems before each test. The measurements were performed in a silent ambient environment with sound pressure levels not exceeding 45 dB. Primary stimuli levels were equalized at 65 dB for DPOAE measurements (L1 = L2). Two separate frequencies (f1 and f2) were set at a f2:f1 ratio equivalent to 1:22 to obtain the strongest responses. DPOAE measurements were performed at frequencies of 2003, 2519, 3175, 3996, 5039, 6351, 8003, and 10,078 Hz, and the results were recorded.
Statistical analysis
Data were analyzed using SPSS 11.0 for Windows (SPSS Inc., Chicago, IL, USA). The results for all items were expressed as mean ± SEM, assessed within 95% reliance and at a significance level of P < 0.05. Wilcoxon's paired-t test was used to analyze the data.
Results
Initially, the duration of the study was planned as 10 days. The rats completed the first 5 days of the study without any loss. However, on the sixth day, 9 rats died because of enteritis, nephrotoxic effects, and weight loss possibly due to cisplatin toxicity; consequently, the measurements were terminated because of scarcity of experimental animals. 3.1. Control group DPOAE measurements were performed on days 0, 1, 2, and 5, and a statistically significant difference did not exist at frequencies of 2003-10,078 Hz (P > 0.05) (Figure) .
Cisplatin group
No statistically significant difference was found between DPOAE measurements performed on days 0 and 1, days 0 and 2, or days 1 and 2. However, statistically significant differences were found between measurements taken on days 0 and 5 at all frequencies; between days 1 and 5 in measurements performed at the frequencies of 3175, 3996, 5039, 6351, 8003, and 10,078 Hz; and between days 2 and 5 in measurements performed at the frequencies of 2003, 3175, 3996, 5039, 6351, 8003, and 10,078 Hz (P < 0.05) (Figure) .
Cisplatin + lycopene group
In DPOAE measurements, no statistically significant difference was found between the measurements of days 0 and 1, days 0 and 2, or days 1 and 2. Statistically significant differences were found between the measurements performed on days 0 and 5 at the frequencies of 3175, 3996, 5039, 6351, 8003, and 10,078 Hz; between the measurements of days 1 and 5 at frequencies of 3175, 3996, 5039, 6351, 8003, and 10,078 Hz; and between the measurements taken on days 2 and 5 at frequencies of 3996, 5039, 6351, 8003, and 10,078 Hz (P < 0.05). Contrary to the cisplatin group, in the cisplatin + lycopene group, the hearing ability was observed as being preserved in the measurements of days 0 
Discussion
Cisplatin is an antineoplastic drug that is frequently used in head, neck, testicular, and ovarian malignancies. Many investigations have been performed to ensure the safe usage of this chemotherapeutic agent due to its important adverse effects, such as ototoxicity. For instance, in studies performed by Teranishi and Nakashima and by Kalkanis et al., reductions were observed in hearing loss and cochlear damage by using systemic vitamin E administration (1, 13) . In similar studies, the potentially prophylactic effects of different antioxidant agents, e.g., erdosteine, aminoguanidine, and caffeic acid, were demonstrated (3) (4) (5) .
The antioxidant effect of the carotenoid family is a result of their extended tetraterpene chemical configuration, in which a total of 40 carbon units are bound end-toend with single and double conjugated bonds. The free radical-neutralizing property of this chemical formation, with its protective effects against some cancer types, cardiac dysfunctions, and degenerative eye diseases, has been revealed in many investigations. As a result of these studies, the prominent antioxidant effect of lycopene is associated with preventing ROS damage via free radical scavenging and detoxifying lipid peroxides (14) (15) (16) .
Studies performed with lycopene from the carotenoid family have demonstrated that lycopene induces decreased levels of malondialdehyde, which is the end product of fatty acid oxidation and is known to correlate with the degree of oxidative damage. However, as shown in various studies, lycopene also increases activities of endogenous antioxidants such as superoxide dismutase and glutathione peroxidase (14, 17, 18) .
In a previous study, the antioxidant effects of synthetic and naturally occurring (i.e. found in tomatoes) forms of lycopene were compared with placebo-group patients. Decreased lipid peroxidation and oxidative stress were found in both lycopene-supplementing groups when compared with the placebo-group patients. In comparative analysis, a statistically significant difference was noted between the lycopene groups. As a result, it was suggested that dietary intake of natural lycopene is favorable against oxidative stress; however, the synthetic form is more bioavailable and more effective (19) .
The protective effect of lycopene against chemotherapy agent toxicities such as cisplatin-induced nephrotoxicity, doxorubicin-induced myocardial or kidney toxicity, gentamycin-induced nephrotoxicity, and oxidative stress was shown in animal studies (20) (21) (22) .
In the present study, we evaluated the protective effect of this potent antioxidant agent against ototoxicity induced by cisplatin. However, the study was terminated earlier than planned due to the loss of the majority of the rats on the sixth day, from the systemic toxicity of cisplatin. The results of the DPOAE measurements performed in cisplatin-administered rats revealed statistically significant deteriorations at all frequencies, while hearing ability was preserved at low frequencies in the cisplatin + lycopeneadministered group. These data suggest that lycopene can prevent the development of ototoxicity, especially at lower frequencies. Future studies on this issue with longer durations and different dose ranges may contribute to the identification of potentially prophylactic effects of lycopene against cisplatin ototoxicity at low and higher frequencies, as well.
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